Sonderveranstaltung 2: The Politics of Technology: A Primer on Innovative Developments that Governments Should Embrace to Kick-Start GNP
-
Hotel Alpbacherhof
Breakout
/
in englischer SpracheDas Bestreben nationaler Staaten ist es, ihren Bürgern eine bessere Lebensqualität zu bieten. Dies betrifft vor allem einen verbesserten Zugang zur Gesundheitsfürsorge, Bildung, Verkehrswesen sowie Luxusgüter und öffentliche Einrichtungen. Diese Services sind nicht kostenlos, und die Fähigkeit europäischer Regierungen, ihre Wahlversprechen auch einzuhalten, hängt direkt damit zusammen, wie gut es ihnen gelingt, Reichtum zu schaffen.
Innerhalb eines engen Zeitrahmens am Morgen des 27. August wird unsere Arbeitsgruppe die Gesetze, Richtlinien und lokalen Traditionen beleuchten, die direkten Einfluss auf Innovation und Technologie und damit auf die Bildung von Reichtum auf nationaler Ebene haben. Insbesondere wird unsere international besetzte Sprechergruppe die Möglichkeiten nationaler Politik zur Steigerung der globalen Wettbewerbsfähigkeit untersuchen.
| |||||
| |||||
| |||||
| |||||
| |||||
| |||||
| |||||
| |||||
| |||||
|
Ph.D. David BROWN
Chief Executive Officer, Cellzome AG
| Since September 2002 President and CEO of Cellzome, an emerging Biopharmaceutical company based in Cambridge, UK, and Heidelberg, Germany | |
| At Cellzome, Dr. Brown has focused the company's proteomics platform to create drugs to treat Alzheimer's disease, diabetes, and inflammatory diseases. | |
| Dr Brown 28 years experience in major Pharma and has served with 4 of the top 10 Pharma companies: Roche, Glaxo, Pfizer and Zeneca. | |
| Global Head of Drug Discovery, Roche Pharma, Basel, Switzerland, where he had responsibility for the output of clinical candidate drugs from approximately 2000 scientists across Roche's 5 research sites. | |
| Extensive experience of pharmaceutical R&D in all phases from early discovery through clinical trials. | |
| Experience of leading research in all major disease areas. | |
| Whilst at Pfizer he was named co-inventor on the patent for Viagra and he led the team that developed Viagra through to proof of concept (clinical efficacy) in man. | |
| At Roche, in addition to his role in leading Discovery, Dr Brown also served on the committee responsible for clinical drug development and he was a core member of the business development committee responsible for in-licensing of products and for technology agreements and acquisitions. |
Dr. Andrew DEARING
Secretary General, European Industrial Research Management Association - EIRMA
| 1978 | Graduated from University of Oxford with Doctor of Philosophy in Chemistry. |
| 1978-1998 | Range of positions in R&D management and in corporate strategy within the Royal Dutch/Shell group of companies. |
| 1980-1981 | Visiting Lecturer at the University of California, San Francisco. |
| In 1998, he was seconded to the World Business Council for Sustainable Development as Programme Director for Innovation and Technology. | |
| Founding member of the UNEP Steering Committees establishing the Millennium Ecosystem Assessment and the World Conservation Monitoring Centre and contributed to the third round of the Intergovernmental Panel on Climate Change | |
| Expert advisor to the European Commission, the OECD and several national governments on matters of innovation and industrial research policy. | |
| Since 2000 Secretary General, European Industrial Research Management Association - EIRMA |
Dr. Hanns R. GLATZ
Representative for EU Affairs, CNC - Communications & Network Consulting AG, Brussels
| Studied law, politics and economics, University of Vienna | |
| Doctor of laws, University of Vienna | |
| MA European Studies, College of Europe in Bruges | |
| 1968 | Private Office, Austrian Minister of Agriculture, Vienna |
| 1970 | Ford Europe, Governmental Affairs Office, Brussels |
| 1979 | Secretary General of the CLCA, the EU federation of national motor vehicle manufacturers associations, Brussels |
| 1989-2009 | Head, Corporate Representative Office for European Affairs, Daimler-Benz (now Daimler AG), Brussels |
| since 2010 | Head of Brussels Office, CNC - Communications & Network Consulting AG, International |
Dr. Giselher GUTTMANN
Universitätsprofessor emeritus
| 1963 | Promotion |
| 1959 | Mitarbeiter am Institut für Psychologie Wien |
| 1961 | Assistent in Erlangen |
| 1964 | Assistent in Wien |
| 1968 | Habilitation und Berufung auf ein Extraordinariat |
| 1972 | Ordinariat für Angewandte Psychologie |
| 1973 | Ordinariat für Allgemeine Psychologie (Nachfolge Rohracher) |
| 1975 | Dekan der Philosophischen Fakultät |
| 1976 | Dekan der Grund- und Integrativwissenschaftlichen Fakultät |
| 1983 | Mitglied der Österreichischen Akademie der Wissenschaften |
| 2000 | Gründungsrektor der Universität für Humanwissenschaften in Liechtenstein |
Gaston MESKENS
SCK-CEN, Adviser, Applied Systems Analysis and Technology Assessment
| Academic degrees in theoretical physics and nuclear engineering from the University of Ghent, Belgium | |
| Within the framework of the Project on Integration of Social Aspects into Nuclear Research (PISA) of the SCK-CEN, he is PISA Program Manager and research track leader of the 'Sustainability and Nuclear Development' project (SuND) | |
| He is a member of IAEA & OECD/NEA expert groups on the technical and socio-economical aspects of (nuclear) technology | |
| He is invited independent expert to the FORATOM Task Force on Sustainable Development, the FORATOM Climate Change Working Group and the World Nuclear Association Sustainable Development Strategy Group | |
| Since two years, he is the European Nuclear Society representative to the negotiations within the United Nations Framework Convention on Climate Change (UNFCCC) and to the United Nations Commission on Sustainable Development (CSD) | |
| As the chairman of the European Nuclear Society Program Committee, he is responsible for the ENS conference profiling and long term strategy | |
| Within SCK-CEN, he is project leader of the International School for Radiological Protection (isRP) |
Dr. techn. Erkki ORMALA
Vice President, Technology Policy, Nokia Corporation
| 1974 | M.Eng. Degree |
| 1986 | Dr.Tech. Degree, Helsinki University of Technology |
| 1974-1987 | Research engineer at the Technical Research Centre of Finland |
| 1976 | visiting scholar at Stanford University in the USA |
| 1982 | International Institute of Applied Systems Analysis in Austria. |
| 1987-1999 | Secretary of the Science and Technology Policy Council of Finland |
| 1999 | he joined Nokia Group as Director, Technology Policy. |
| His responsibilities cover technology policy, knowledge management, university co-operation, future watch and issues relating to information society. |
PhD Ferdinando SAMARIA
Chief Financial Officer, UniCredit Banca Mobiliare (UBM)
| 1991 | BA |
| 1994 | MA and PhD in Engineering from Trinity College, Cambridge University |
| 2 years researching in the field of Image Processing with Olivetti Research Laboratories in Cambridge | |
| 1996 | joins Credit Suisse Financial Products, London |
| 1998 | moves to UniCredito Italiano as managing director in the area of risk management |
Wim PHILIPPA
Secretary General, The European Round Table of Industrialists, Brussels
| Business, marketing and law degrees | |
| 1970 | Heineken Breweries in the Netherlands, management positions covering South & Central America, the Caribbean and Western Europe |
| 1979 | joined Ciba-Geigy in the Netherlands and held subsequent commercial and managerial positions in Zimbabwe and Greece |
| 1994-1998 | Head of the European Union Relations Office of Ciba-Geigy in Brussels, subsequently ran a political and legal consultancy firm |
| Since 1998 appointed Secretary General of the European Round Table of Industrialists |
Andrew CRAVEN
Communications project manager in the pharmaceuticals development department of the Roche Group, based in Basel, Switzerland Director, Lexicon Consulting, Basel
| Degrees in Physics and Communications | |
| Started communications career in radio journalism | |
| Later recruited into first the chemicals, then pharmaceutical industries as a communications expert | |
| Moderator/facilitator at senior level data-discovery and experience-sharing meetings in the areas of business, law-enforcement and politics | |
| Proprietor of Lexicon, a communications agency providing consultancy in the areas of strategic public and media relations, and in reputation and issue management | |
| Communications project manager in the pharmaceuticals development department of the Roche Group, based in Basel, Switzerland |
